nach oben

Tumor Biology

Erschienen in:

11.12.2015 | Review

Circulating epigenetic biomarkers in melanoma

verfasst von: Yu Xin, Zheng Li, Matthew T.V. Chan, William Ka Kei Wu

Erschienen in: Tumor Biology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Recent researches have shed new light on the importance of epigenetic alterations, including promoter hypermethylation and microRNA dysregulation, in the initiation and progression of melanoma. The clinical utilization of circulating epigenetic markers in melanoma has also been investigated. In this review, we explored the literature and summarized the latest progress in the discovery of circulating epigenetic markers, namely methylated DNA and microRNAs, for non-invasive diagnosis of melanoma, as well as their measurability and predictability. We also discussed the utility of these epigenetic markers as novel prognostic and predictive markers and their association with melanoma clinical phenotypes, including recurrence and patients’ survival. Large-cohort validations are warranted to maximize the clinical utilization of these markers.

Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, Pinner S, et al. Intronic mir-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell. 2010;40:841–9.CrossRefPubMedPubMedCentral

Margue C, Philippidou D, Reinsbach SE, Schmitt M, Behrmann I, Kreis S. New target genes of MITF-induced microRNA-211 contribute to melanoma cell invasion. PLoS One. 2013;8:e73473.CrossRefPubMedPubMedCentral

Sari Aslani F, Geramizadeh B, Dehghanian AR. Comparison of c-Kit expression between primary and metastatic melanoma of skin and mucosa. Med J Islam Republic Iran. 2015;29:203.

Walesch SK, Richter AM, Helmbold P, Dammann RH. Claudin11 promoter hypermethylation is frequent in malignant melanoma of the skin, but uncommon in nevus cell nevi. Cancer. 2015;7:1233–43.CrossRef

Watts JM, Kishtagari A, Hsu M, Lacouture ME, Postow MA, Park JH, et al. Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a surveillance, epidemiology and end results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. Br J Haematol. 2015;171:84–90.CrossRefPubMedPubMedCentral

Boniol M, Autier P, Gandini S. Melanoma mortality following skin cancer screening in Germany. BMJ open. 2015;5:e008158.CrossRefPubMedPubMedCentral

Little EG, Eide MJ. Update on the current state of melanoma incidence. Dermatol Clin. 2012;30:355–61.CrossRefPubMed

Brenner H. Mortality from malignant melanoma in an era of nationwide skin cancer screening. Dtsch Arztebl Int. 2015;112:627–8.PubMedPubMedCentral

Merrill RM. Risk-adjusted melanoma skin cancer incidence rates in whites (United States). Melanoma Res. 2011;21:535–40.CrossRefPubMed

10.

Majewski W, Stanienda K, Wicherska K, Ulczok R, Wydmanski J. Treatment outcome and prognostic factors for malignant skin melanoma treated with radical surgery. Asian Pac J Cancer Prev. 2015;16:5709–14.CrossRefPubMed

11.

Crocetti E, Mallone S, Robsahm TE, Gavin A, Agius D, Ardanaz E, Lopez MC, Innos K, Minicozzi P, Borgognoni L, Pierannunzio D, Eisemann N: Survival of patients with skin melanoma in Europe increases further: results of the EUROCARE-5 study. Eur J Cancer 2015

12.

Coups EJ, Manne SL, Stapleton JL, Tatum KL, Goydos JS: Skin self-examination behaviors among individuals diagnosed with melanoma. Melanoma research 2015

13.

Yu X, Li Z. Epigenetic deregulations in chordoma. Cell Prolif. 2015;48:497–502.CrossRefPubMed

14.

Sato F, Tsuchiya S, Meltzer SJ, Shimizu K. MicroRNAs and epigenetics. FEBS J. 2011;278:1598–609.CrossRefPubMed

15.

Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP. Epigenetic biomarkers in lung cancer. Cancer Lett. 2014;342:200–12.CrossRefPubMed

16.

Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia. 2010;15:5–17.CrossRefPubMedPubMedCentral

17.

Lujambio A, Portela A, Liz J, Melo SA, Rossi S, Spizzo R, et al. CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene. 2010;29:6390–401.CrossRefPubMedPubMedCentral

18.

Niles LP, Pan Y, Kang S, Lacoul A. Melatonin induces histone hyperacetylation in the rat brain. Neurosci Lett. 2013;541:49–53.CrossRefPubMed

19.

Sigalotti L, Covre A, Fratta E, Parisi G, Colizzi F, Rizzo A, et al. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med. 2010;8:56.CrossRefPubMedPubMedCentral

20.

Mazar J, DeBlasio D, Govindarajan SS, Zhang S, Perera RJ. Epigenetic regulation of microRNA-375 and its role in melanoma development in humans. FEBS Lett. 2011;585:2467–76.CrossRefPubMed

21.

Howell Jr PM, Liu S, Ren S, Behlen C, Fodstad O, Riker AI. Epigenetics in human melanoma. Cancer Control. 2009;16:200–18.PubMed

22.

Bonazzi VF, Stark MS, Hayward NK. MicroRNA regulation of melanoma progression. Melanoma Res. 2012;22:101–13.CrossRefPubMed

23.

Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, et al. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget. 2012;3:1011–25.CrossRefPubMedPubMedCentral

24.

Wilmott JS, Colebatch AJ, Kakavand H, Shang P, Carlino MS, Thompson JF, et al. Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Mod Pathol. 2015;28:884–94.CrossRefPubMed

25.

Voso MT, Lo-Coco F, Fianchi L. Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Oncol. 2015;27:532–9.CrossRefPubMed

26.

Duvic M. Histone deacetylase inhibitors for cutaneous T-cell lymphoma. Dermatol Clin. 2015;33:757–64.CrossRefPubMed

27.

Hrabeta J, Stiborova M, Adam V, Kizek R, Eckschlager T. Histone deacetylase inhibitors in cancer therapy. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czec. 2014;158:161–9.

28.

Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, et al. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol. 2013;133:1278–85.CrossRefPubMed

29.

Hoshimoto S, Kuo CT, Chong KK, Takeshima TL, Takei Y, Li MW, et al. AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol. 2012;132:1689–97.CrossRefPubMedPubMedCentral

30.

Greenberg ES, Chong KK, Huynh KT, Tanaka R, Hoon DS. Epigenetic biomarkers in skin cancer. Cancer Lett. 2014;342:170–7.CrossRefPubMed

31.

Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y, et al. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer. 2015;18:43–54.CrossRefPubMed

32.

Wiklund ED, Gao S, Hulf T, Sibbritt T, Nair S, Costea DE, et al. MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma. PLoS One. 2011;6:e27840.CrossRefPubMedPubMedCentral

33.

Tsumagari K, Baribault C, Terragni J, Chandra S, Renshaw C, Sun Z, et al. DNA methylation and differentiation: HOX genes in muscle cells. Epigenetics Chromatin. 2013;6:25.CrossRefPubMedPubMedCentral

34.

Zhang Z, Tang H, Wang Z, Zhang B, Liu W, Lu H, et al. Mir-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma. Mol Cancer. 2011;10:124.CrossRefPubMedPubMedCentral

35.

Wong KY, Huang X, Chim CS. DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis. 2012;33:1629–38.CrossRefPubMed

36.

Taberlay PC, Jones PA. DNA methylation and cancer. Prog Drug Res. 2011;67:1–23.PubMed

37.

Lauss M, Ringner M, Karlsson A, Harbst K, Busch C, Geisler J, et al. DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. BMC Med Genomics. 2015;8:73.CrossRefPubMedPubMedCentral

38.

Liu Y, Dong Z, Liang J, Guo Y, Guo X, Shen S, Kuang G, Guo W: Methylation-mediated repression of potential tumor suppressor miR-203a and miR-203b contributes to esophageal squamous cell carcinoma development. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2015

39.

Otsubo T, Hagiwara T, Tamura-Nakano M, Sezaki T, Miyake O, Hinohara C, et al. Aberrant DNA hypermethylation reduces the expression of the desmosome-related molecule periplakin in esophageal squamous cell carcinoma. Cancer Med. 2015;4:415–25.CrossRefPubMedPubMedCentral

40.

Nazarian R, Jazirehi AR. TFPI2 methylation can serve as an epigenetic biomarker of metastatic melanoma. Epigenomics. 2013;5:252–3.PubMed

41.

Perez-Ramirez C, Canadas-Garre M, Molina MA, Faus-Dader MJ, Calleja-Hernandez MA. PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics. 2015;16:1843–62.CrossRefPubMed

42.

Zheng J, Dai Y, Yang Z, Yang L, Peng Z, Meng R, Xiong Y, He J: Ezrin-radixin-moesin-binding phosphoprotein-50 regulates EGF-induced AKT activation through interaction with EGFR and PTEN. Oncology reports 2015. doi: 10.3892/or.2015.4375.

43.

Du J, Wang L, Li C, Yang H, Li Y, Hu H, Li H, Zhang Z: MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2015

44.

Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 2006;66:6546–52.CrossRefPubMed

45.

Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene. 2004;23:4014–22.CrossRefPubMedPubMedCentral

46.

Mori T, Martinez SR, O’Day SJ, Morton DL, Umetani N, Kitago M, et al. Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res. 2006;66:6692–8.CrossRefPubMedPubMedCentral

47.

Mori T, O’Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol. 2005;23:9351–8.CrossRefPubMedPubMedCentral

48.

Yu X, Li Z, Yu J, Chan MT, Wu WK. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. Cell Prolif. 2015;48:503–10.CrossRefPubMed

49.

Li Z, Yu X, Shen J, Liu Y, Chan MT, Wu WK. MicroRNA dysregulation in rhabdomyosarcoma: a new player enters the game. Cell Prolif. 2015;48:511–6.CrossRefPubMed

50.

Yu X, Li Z. The role of microRNAs expression in laryngeal cancer. Oncotarget. 2015;6:23297–305.CrossRefPubMedPubMedCentral

51.

Li Z, Yu X, Shen J, Jiang Y. MicroRNA dysregulation in uveal melanoma: a new player enters the game. Oncotarget. 2015;6:4562–8.CrossRefPubMedPubMedCentral

52.

Yu X, Li Z, Chen G, Wu WK. MicroRNA-10b induces vascular muscle cell proliferation through Akt pathway by targeting TIP30. Curr Vasc Pharmacol. 2015;13:679–86.CrossRefPubMed

53.

Yu X, Li Z, Liu J. MiRNAs in primary cutaneous lymphomas. Cell Prolif. 2015;48:271–7.CrossRefPubMed

54.

Li Z, Yu X, Shen J, Chan MT, Wu WK. MicroRNA in intervertebral disc degeneration. Cell Prolif. 2015;48:278–83.CrossRefPubMed

55.

Li Z, Yu X, Shen J, Law PT, Chan MT, Wu WK. MicroRNA expression and its implications for diagnosis and therapy of gallbladder cancer. Oncotarget. 2015;6:13914–24.CrossRefPubMedPubMedCentral

56.

Yu X, Li Z, Shen J, Wu WK, Liang J, Weng X, et al. MicroRNA-10b promotes nucleus pulposus cell proliferation through RhoC-Akt pathway by targeting HOXD10 in intervetebral disc degeneration. PLoS One. 2013;8:e83080.CrossRefPubMedPubMedCentral

57.

Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J, et al. By downregulating TIAM1 expression, microRNA-329 suppresses gastric cancer invasion and growth. Oncotarget. 2015;6:17559–69.CrossRefPubMedPubMedCentral

58.

Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672–5.CrossRefPubMed

59.

Ludwig N, Nourkami-Tutdibi N, Backes C, Lenhof HP, Graf N, Keller A, et al. Circulating serum miRNAs as potential biomarkers for nephroblastoma. Pediatr Blood Cancer. 2015;62:1360–7.CrossRefPubMed

60.

Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Intl J Cancer J Intl Du Cancer. 2013;132:116–27.CrossRef

61.

Wei X, Chen D, Lv T, Li G, Qu S: Serum microRNA-125b as a potential biomarker for glioma diagnosis. Molecular neurobiology 2014

62.

Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB, et al. Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer. 2015;112(Suppl):1241–6.CrossRefPubMedPubMedCentral

63.

Cleys ER, Halleran JL, McWhorter E, Hergenreder J, Enriquez VA, da Silveira JC, et al. Identification of microRNAs in exosomes isolated from serum and umbilical cord blood, as well as placentomes of gestational day 90 pregnant sheep. Mol Reprod Dev. 2014;81:983–93.CrossRefPubMed

64.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.CrossRefPubMedPubMedCentral

65.

Greenberg E, Besser MJ, Ben-Ami E, Shapira-Frommer R, Itzhaki O, Zikich D, et al. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers. 2013;18:502–8.CrossRefPubMed

66.

Shiiyama R, Fukushima S, Jinnin M, Yamashita J, Miyashita A, Nakahara S, et al. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Res. 2013;23:366–72.CrossRefPubMed

67.

Ono S, Oyama T, Lam S, Chong K, Foshag LJ, Hoon DS. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget. 2015;6:7053–64.CrossRefPubMedPubMedCentral

68.

Kanemaru H, Fukushima S, Yamashita J, Honda N, Oyama R, Kakimoto A, et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci. 2011;61:187–93.CrossRefPubMed

69.

Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, et al. The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: a microRNA expression analysis. EBioMed. 2015;2:671–80.CrossRef

70.

Friedman EB, Shang S, de Miera EV, Fog JU, Teilum MW, Ma MW, et al. Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med. 2012;10:155.CrossRefPubMedPubMedCentral

71.

Fleming NH, Zhong J, da Silva IP, Vega-Saenz de Miera E, Brady B, Han SW, et al. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer. 2015;121:51–9.CrossRefPubMed

72.

Tian R, Liu T, Qiao L, Gao M, Li J. Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma. Int J Clin Exp Pathol. 2015;8:3097–103.PubMedPubMedCentral

Titel: Circulating epigenetic biomarkers in melanoma
verfasst von: Yu Xin
Zheng Li
Matthew T.V. Chan
William Ka Kei Wu
Publikationsdatum: 11.12.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 2/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4599-0

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Circulating epigenetic biomarkers in melanoma

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Low 25-OH vitamin D levels at time of diagnosis and recurrence of ovarian cancer

In situ dendritic cell vaccination for the treatment of glioma and literature review

Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells

The clinical utility of image-guided iodine-125 seed in patients with unresectable pancreatic cancer

Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation

Long non-coding RNA MALAT1 modulates radiosensitivity of HR-HPV+ cervical cancer via sponging miR-145

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie